Clinical trials: Neoadjuvant Treatment
Breast Cancer
Phase II Neoadjuvant in Inflammatory Breast Cancer
The goal of this clinical research study is to learn how well lapatinib taken alone, followed by taking lapatinib with paclitaxel, and then taking lapatinib with 5-fluorouracil, epirubicin, and cyclophosphamide (FEC75) works to…
- Trial name
- NCT00756470
- Testing
- Lapatinib, Paclitaxel, 5-Fluorouracil (5-FU)
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- M.D. Anderson Cancer Center
Breast Cancer Stage II
Anlotinib Combined With Chemotherapy and Neoadjuvant Therapy for Hormone Receptor-positive HER-2 Negative Breast Cancer
Anlotinib is an oral multi-targeted tyrosine kinase inhibitor (TKI) that strongly inhibits VEGFR, PDGFR, FGFR, and c-kit. Combining anti-angiogenesis with chemotherapy yielded increased response rates in patients with early-stage…
- Trial name
- ACNTBC (NCT05558722)
- Testing
- Anlotinib
- Where
- China
- Volunteers
- 31 people
- Sponsor
- Xijing Hospital
Prostate Cancer
NeoAdjuvant Theranostic Lutetium Study: The Nautilus Trial
To learn if the proposed dose of 177Lu rhPSMA-10.1 is safe. Phase 2 will open if the Phase 1 dose is found to be safe. To learn about the safety and effects of 177Lu rhPSMA-10.1 alone and with androgen deprivation therapy (ADT)…
- Trial name
- NCT06066437
- Testing
- Arm A: 177Lu rhPSMA-10.1, Arm B: 177Lu rhPSMA-10.1 plus Degarelix
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- M.D. Anderson Cancer Center
Melanoma Stage IIIB-IV
NeoLIPA: Neoadjuvant LTX-315 in Combination with Pembrolizumab in Resectable Stage III/IV Melanoma
This clinical trial aims to evaluate the effectiveness of a new treatment approach for patients with stage III or IV melanoma that has spread to other parts of the body but can still be surgically removed.
- Trial name
- NeoLIPA (NCT06651151)
- Testing
- LTX-315 + pembrolizumab
- Where
- Norway
- Volunteers
- 27 people
- Sponsor
- Oslo University Hospital
Rectal Cancer
Watchful Waiting for Complete Responders to Therapy in Rectal Cancer
The purpose of this project is to determine if in a selected group of patients, at higher risk of wound dehiscence and other complications, treatment by local excision and management by a "watchful waiting" or an initial…
- Trial name
- NCT05526079
- Testing
- Watchfuf waiting
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Henry Ford Health System
Breast Cancer, Breast Neoplasms
Neoadjuvant Ontruzant (SB3) in Patients With HER2-positive Early Breast Cancer: An Open-Label (NeoON)
The treatment of patients with HER2 positive early breast cancer has continuously improved over the last decades. Up to now both, trastuzumab and pertuzumab are approved in combination with chemotherapy (CTX) not only for the…
- Conditions
- Breast Cancer, Breast Neoplasms, Breast Cancer Female, HER2-positive Breast Cancer
- Trial name
- NeoON (NCT05036005)
- Testing
- Ontruzant, Chemotherapy, Pertuzumab
- Where
- 11 sites in Germany
- Volunteers
- 108 people
- Sponsor
- Institut fuer Frauengesundheit
Hepatocellular Carcinoma, Portal Vein Thrombosis
Neo-TACE-HAIC for PVTT-HCC
Hepatocellular carcinoma (HCC) patients is a common disease in the East Asia. During the disease course, 20%-50% patients suffered portal vein tumor thrombus (PVTT), which is characterized with poor outcome and low response for…
- Trial name
- NeoconceptC (NCT04181931)
- Testing
- neo-TACE-HAIC+Surgery, Surgery alone
- Where
- 2 sites in China
- Volunteers
- 320 people
- Sponsor
- Sun Yat-sen University
HR+HER2- Breast Cancer
Neoadjuvant Chemotherapy + PD-1 Inhibitor+Different Radiotherapy Fractionations for HR+/HER2- Breast Cancer
For the hormone receptor-positive (HR+)/human epidermal growth factor receptor 2-negative (HER2-) subtype of breast cancer, although surgical, radiotherapy, and endocrine treatments have shown better survival, this subtype has a…
- Trial name
- NCT06639672
- Testing
- Chemotherapy+PD-1 inhibitor+8Gy x 3f, Chemotherapy+PD-1 inhibitor+16Gy x 1f, Chemotherapy+PD-1 inhibitor+2.67Gy x 15f
- Volunteers
- 60 people
- Sponsor
- Lei Liu
Borderline Resectable Pancreatic Cancer
Neoadjuvant Nab-Paclitaxel and S-1 in Borderline Resectable Pancreatic Cancer
This study was a single-arm multicenter prospective phase II clinical study, designed to evaluate the efficacy and safety of neoadjuvant nab-paclitaxel combined with S-1 in patients with borderline resectable pancreatic cancer.
- Trial name
- NCT03850769
- Testing
- nab-paclitaxel and S-1
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Peking Union Medical College Hospital
Stage III Adult Soft Tissue Sarcoma
Docetaxel, Gemcitabine and Pazopanib as Treatment for Soft Tissue Sarcoma
Chemotherapy treatment with docetaxel and gemcitabine is a standard treatment for patients with soft tissue sarcoma. This study is designed to explore whether the addition of tyrosine kinase inhibitor pazopanib enhances the…
- Trial name
- NCT01719302
- Testing
- Gemcitabine, Docetaxel, Pazopanib
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- University of Vermont
Bladder Cancer
Evaluating the Efficacy of Neoadjuvant Chemotherapy Drugs Based on Organoid Technology
This study, through a clinical controlled trial, compared the one-year, three-year, and five-year overall survival rates between patients receiving a treatment plan guided by organoid drug sensitivity and those receiving…
- Trial name
- NCT07379281
- Testing
- Organoid culture
- Where
- China
- Volunteers
- 254 people
- Sponsor
- Qilu Hospital of Shandong University
Acute Myeloid Leukemia
Gemtuzumab Ozogamicin in Induction and Glasdegib in Postremission Therapy in Patients With AML (Acute Myeloid Leukemia)
The study is a randomized phase III trial with a 2x2 factorial design with measurable residual disease and event-free survival as primary endpoints, respectively.
- Trial name
- GnG (NCT04093505)
- Testing
- Gemtuzumab Ozogamicin 147, Gemtuzumab Ozogamicin 1, Glasdegib
- Where
- Germany
- Volunteers
- 28 people
- Sponsor
- University Hospital Heidelberg
Melanoma Stage III, Melanoma
Adjuvant Treatment Determined By Pathological Response To Neoadjvuant Nivolumab
Subjects with resectable melanoma will receive neoadjuvant nivolumab followed by surgical resection. Post-operatively, subjects will receive open-label treatment with up to 1 year of adjuvant nivolumab or ipilimumab plus…
- Trial name
- NCT04013854
- Testing
- nivolumab, Ipilimumab
- Where
- 3 sites in United States
- Volunteers
- 67 people
- Sponsor
- Abramson Cancer Center at Penn Medicine
PD-1, Neoadjuvant Chemoradiotherapy
Neoadjuvant Sintilimab Plus Chemoradiotherapy for Locally Advanced Adenocarcinoma of Esophagogastric Junction
The purpose of this study is to access the safety and efficacy of neoadjuvant Immunotherapy (Sintilimab, PD-1 inhibitor) combined with chemotherapy (S-1+Oxaliplatin) and radiotherapy for locally advanced esophagogastric junction…
- Conditions
- PD-1, Neoadjuvant Chemoradiotherapy, Gastroesophageal Junction Cancer
- Trial name
- NCT06250894
- Testing
- PD-1inhibitor
- Where
- China
- Volunteers
- 32 people
- Sponsor
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Lung Cancer
Neoadjuvant IRESSA As Single Agent PreopTherapy for NSCLC With Molecular Correlates
RATIONALE: Gefitinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving gefitinib before surgery may shrink the tumor so it can be removed.
- Trial name
- NCT00104728
- Testing
- ZD1839
- Where
- United States
- Volunteers
- 42 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Breast Cancer
Neoadjuvant Chemotherapy With a Combination of Pegylated Liposomal Doxorubicin (Caelyx®) and Paclitaxel in Breast Cancer
In this study, PLD, an anthracycline encapsulated in stealth liposomes, which are believed to efficiently deliver the doxorubicin within the tumour mass with less toxicity compared with standard doxorubicin formulation was used.
- Trial name
- NCT03221881
- Testing
- Pegylated Liposomal Doxorubicin and docetaxel
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Hebei Medical University Fourth Hospital
Mammary Cancer
Omission of Surgery and Sentinel Lymph Node Dissection in Clinically Low-risk HER2positive Breast Cancer With High HER2 Addiction and a Complete Response Following Standard Anti- HER2-based Neoadjuvant Therapy (ELPIS Trial)
This is a prospective, single arm, open-label, exploratory study in women with primary operable HER2-positive, HER2-enriched(HER2-E)/ERBB2-high breast cancer according to PAM50 intrinsic subtype and a ERBB2 pre-defined cutoff…
- Trial name
- ELPIS (NCT04301375)
- Testing
- Pertuzumab and trastuzumab FDC subcutaneous, Paclitaxel, TDM1
- Where
- Spain
- Volunteers
- 27 people
- Sponsor
- David Garcia Cinca
Head and Neck Squamous Cell Carcinoma, Low-dose Radiotherapy
A Clinical Trial Comparing Low-Dose RT + Targeted Therapy+ Immunotherapy vs Targeted Therapy+ Immunotherapy Alone as Neoadjuvant Therapy in Operable HNSCC Patients.
This study aimed to compare the efficacy of neoadjuvant low-dose radiotherapy combined with targeted therapy and immunotherapy versus targeted therapy and immunotherapy alone in patients with resectable head and neck squamous…
- Conditions
- Head and Neck Squamous Cell Carcinoma, Low-dose Radiotherapy, Immunotherapy, Targeted Therapy
- Trial name
- NCT07040956
- Testing
- Tislelizumab, Afatinib, Low dose radiotherapy
- Where
- China
- Volunteers
- 98 people
- Sponsor
- West China Hospital
Leukemia, Myeloid, Acute
Safety and Efficacy Study of Idarubicin Dose Intensification to Treat Acute Myeloid Leukemia
The purpose of this study is to determine whether idarubicin dose intensification is safe and effective as a remission induction therapy for acute myeloid leukemia.
- Trial name
- IDAML (NCT01518556)
- Testing
- Idarubicin
- Where
- South Korea
- Volunteers
- 49 people
- Sponsor
- Konkuk University Medical Center
Pancreatic Cancer
A Study of Durvalumab in Patients With BR PDA Following Neoadjuvant Therapy and Successful Surgical Resection
This is a two-arm, open-label, phase II study of in adult patients who have successfully undergone R0/R1 resection of PDAs following neoadjuvant chemotherapy and completion of adjuvant chemotherapy.
- Trial name
- NCT03038477
- Testing
- Durvalumab
- Where
- United States
- Volunteers
- healthy volunteers welcome
- Sponsor
- University of Colorado, Denver
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.